Products Erenumab was approved in many countries, in the EU, and in the United States in 2018 as a solution for injection in a prefilled pen and a prefilled syringe (Aimovig, Novartis / Amgen). Structure and properties Erenumab is a human IgG2 monoclonal antibody directed against the CGRP receptor. It has a molecular weight of … Erenumab
Products Risankizumab was approved in the United States and in many countries in 2019 as a solution for injection (Skyrizi). Structure and properties Risankizumab is a humanized IgG1 monoclonal antibody produced by biotechnological methods. Effects Risankizumab (ATC L04AC) has selective immunosuppressive and anti-inflammatory properties. The antibody binds to the p19 subunit of human interleukin-23 (IL-23), … Risankizumab
Products Rituximab is commercially available as a concentrate for the preparation of an infusion solution and as a solution for subcutaneous injection (MabThera, MabThera subcutaneous). It has been approved in many countries and in the United States since 1997 and in the EU since 1998. Biosimilars are available in some countries, including many (2018, Rixathon, … Rituximab
Products Obiltoxaximab was approved in the United States in 2016 as an infusion product (Anthim). It has not yet been registered in many countries. Obiltoxaximab was developed with funding from national organizations and is intended primarily for the treatment of victims of a terrorist attack with anthrax spores (Strategic National Stockpile). Structure and properties Obiltoxaximab … Obiltoxaximab
Products Obinutuzumab is commercially available as a concentrate for the preparation of an infusion solution (Gazyvaro). It has been approved in many countries since 2014. Structure and properties Obinutuzumab is a recombinant, monoclonal, and humanized type II antibody against CD20 of the IgG1 isotype. It has a molecular weight of approximately 150 kDa. Obinutuzumab is … Obinutuzumab
Products Ocrelizumab was approved in many countries and in the United States in 2017 and in the EU in 2018 as an infusion concentrate (Ocrevus). Structure and properties Ocrelizumab is a humanized IgG1 monoclonal antibody with a molecular mass of 145 kDa. It is produced by biotechnological methods. Ocrelizumab is the successor agent to rituximab … Ocrelizumab
Products Satralizumab was approved in many countries in 2020 as a solution for injection (Enspryng). Structure and properties Satralizumab is a humanized IgG2 monoclonal antibody produced by biotechnological methods. Effects Satralizumab (ATC L04AC19) has anti-inflammatory and immunosuppressive properties. The effects are due to binding to the soluble and membrane-bound human IL-6 receptor (IL-6R), preventing signal … Satralizumab
Products Ofatumumab was approved in 2009 as a concentrate for the preparation of an infusion solution for leukemia treatment (Arzerra). In 2020, a solution for injection was approved in the United States for MS treatment (Kesimpta). Structure and properties Ofatumumab is a human IgG1 monoclonal antibody produced by biotechnological methods. It has a molecular mass … Ofatumumab
Products Olaratumab was approved in the United States and EU in 2016 and in many countries in 2017 as a concentrate for the preparation of an infusion solution (Lartruvo). Structure and properties Olaratumab is a human IgG1 monoclonal antibody that binds to PDGFRα. It is produced by biotechnological methods and has a molecular weight of … Olaratumab
Products Eculizumab is commercially available as a concentrate for the preparation of an infusion solution (Soliris). It was approved in many countries in January 2010. Structure and Properties Eculizumab is a monoclonal antibody produced by recombinant DNA technology in NSO cell lines. It is composed of two heavy and two light chains of amino acids … Eculizumab
Products Trastuzumab is commercially available as a lyophilizate for preparation of an infusion concentrate (Herceptin, biosimilars). It has been approved in many countries since 1999 (US: 1998, EU: 2000). In 2016, an additional solution for subcutaneous injection for breast cancer therapy was released in many countries (Herceptin subcutaneous). It was available earlier in other countries. … Trastuzumab
Products Elotuzumab was approved in the United States in 2015 and in the EU and Switzerland in 2016 as a powder for the preparation of an infusion solution (Empliciti). Structure and properties Elotuzumab is a humanized IgG1 monoclonal antibody with a molecular weight of 148.1 kDa. It is produced by biotechnological methods. Effects Elotuzumab (ATC … Elotuzumab